Gil Blum, an analyst from Needham, reiterated the Buy rating on Artiva Biotherapeutics, Inc.. The associated price target remains the same with $18.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Gil Blum has given his Buy rating due to a combination of factors that highlight the potential of Artiva Biotherapeutics, Inc. in the field of rheumatoid arthritis (RA). Artiva’s selection of refractory RA as the lead indication for their AlloNK therapy is strategic, considering the therapy’s clean safety profile in oncology and the advantages of scalability and cost-effectiveness over other treatments like autologous CAR-T. The RA market is less saturated compared to other autoimmune diseases, which presents an opportunity for Artiva to establish a strong foothold.
Furthermore, the ongoing RA study’s promising enrollment rate and the anticipated clinical response data in the first half of 2026 are encouraging indicators of AlloNK’s potential success. The FDA’s Fast Track Designation for AlloNK in RA, along with the possibility of initiating a pivotal study by late 2026 or early 2027, underscores the therapy’s promise. The management’s observation that rituximab’s existing approval in RA may simplify the regulatory pathway further supports the Buy rating and the $18 price target.
According to TipRanks, Blum is a 4-star analyst with an average return of 4.4% and a 39.31% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Celcuity.